Boston, MA 09/03/2014 (wallstreetpr) – GE Healthcare, a health-related unit of General Electric Company (NYSE:GE), announced recently that the U.S. Food and Drug Administration gave its nod to company’s mammography device. According to GE Healthcare, this device has a capability of extracting 3-D images for diagnosis of breast cancer. The three-dimensional results produced by this device can help in easy and faster detecting of the most commonly occurring kind of cancer among women.
About the Device Called SenoClaire
The device is called SenoClaire and is based upon imaging technology. SenoClaire works on a mechanism of combining X-rays which are low radiation dosed and arise from various angles, in order to draw together a larger and better mammogram.
It is worth noticing that SenoClaire in composed of software as well as hardware upgrades, which pertain to Senographe Essential System of General Electric Company (NYSE:GE) Healthcare launched earlier. Senographe Essential System was based on two dimensional technologies, and was an all-inclusive digital mammography structure. But, SenoClaire can be said an updated and much advanced version of that, with better hardware and software characteristics.
Upgraded Technology
As far as the updated and upgraded hardware is concerned, it produces a range of low-dose projection images dependent upon X-ray, of the female breasts, which in turn allow for easy spotting of cancer.
In terms of software upgrade, a diagnosis of breast cancer would be done easily based on cross-sectional breast views through use of low-dose images arising out of X-ray.
Other 3-D Breast Imaging Tools in the Market
It must be noted that General Electric Company (NYSE:GE) Healthcare is not the first company to develop a device like this. Three dimensional imaging of breast had been possible earlier also when Hologic, Inc. (NASDAQ:HOLX) produced a first 3-D breast viewing device in the year 2001. In fact, this device is still the dominating factor in markets today. Apart from this, Siemens AG (ADR) (OTCMKTS:SIEGY) also filed application for approval of 3-dimentional breast imaging equipment with the FDA, in the month of June 2014.
